| Dr Greta Elizabeth Hanson, MD | |
|
96 Colchester Ave, Affiliates In Ob/gyn, Burlington, VT 05401-1417 | |
| (802) 655-0505 | |
| Not Available |
| Full Name | Dr Greta Elizabeth Hanson |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 20 Years |
| Location | 96 Colchester Ave, Burlington, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487872925 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 0420011559 (Vermont) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Obhg Massachusetts Pc | 6709114556 | 3 |
News Archive
Rutin, a bioflavonoid found in certain vegetables and fruits, protects mice against snake venom by minimizing bleeding and inflammation, according to a study performed at the Butantan Institute, a research institution belonging to the government of São Paulo State in Brazil.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.
The Particle Science and Technology Laboratory at Southwest Research Institute has expanded its services to include mask testing in response to the COVID-19 pandemic.
› Verified 7 days ago
| Entity Name | Andover Obstetrics And Gynecological Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831304237 PECOS PAC ID: 0345224648 Enrollment ID: O20040615000829 |
News Archive
Rutin, a bioflavonoid found in certain vegetables and fruits, protects mice against snake venom by minimizing bleeding and inflammation, according to a study performed at the Butantan Institute, a research institution belonging to the government of São Paulo State in Brazil.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.
The Particle Science and Technology Laboratory at Southwest Research Institute has expanded its services to include mask testing in response to the COVID-19 pandemic.
› Verified 7 days ago
| Entity Name | Michael J Grossman Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770530255 PECOS PAC ID: 7517118227 Enrollment ID: O20121106000245 |
News Archive
Rutin, a bioflavonoid found in certain vegetables and fruits, protects mice against snake venom by minimizing bleeding and inflammation, according to a study performed at the Butantan Institute, a research institution belonging to the government of São Paulo State in Brazil.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.
The Particle Science and Technology Laboratory at Southwest Research Institute has expanded its services to include mask testing in response to the COVID-19 pandemic.
› Verified 7 days ago
| Entity Name | Javed Ilyas Siddiqi, M.d. Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225587108 PECOS PAC ID: 1658635503 Enrollment ID: O20180501002554 |
News Archive
Rutin, a bioflavonoid found in certain vegetables and fruits, protects mice against snake venom by minimizing bleeding and inflammation, according to a study performed at the Butantan Institute, a research institution belonging to the government of São Paulo State in Brazil.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.
The Particle Science and Technology Laboratory at Southwest Research Institute has expanded its services to include mask testing in response to the COVID-19 pandemic.
› Verified 7 days ago
| Entity Name | Obhg Massachusetts Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740844083 PECOS PAC ID: 6709114556 Enrollment ID: O20190819001315 |
News Archive
Rutin, a bioflavonoid found in certain vegetables and fruits, protects mice against snake venom by minimizing bleeding and inflammation, according to a study performed at the Butantan Institute, a research institution belonging to the government of São Paulo State in Brazil.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.
The Particle Science and Technology Laboratory at Southwest Research Institute has expanded its services to include mask testing in response to the COVID-19 pandemic.
› Verified 7 days ago
| Entity Name | Obhg Massachusetts Lowell Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861036451 PECOS PAC ID: 0244667574 Enrollment ID: O20200227000344 |
News Archive
Rutin, a bioflavonoid found in certain vegetables and fruits, protects mice against snake venom by minimizing bleeding and inflammation, according to a study performed at the Butantan Institute, a research institution belonging to the government of São Paulo State in Brazil.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.
The Particle Science and Technology Laboratory at Southwest Research Institute has expanded its services to include mask testing in response to the COVID-19 pandemic.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Greta Elizabeth Hanson, MD 15 Hawthorne Cir, South Burlington, VT 05403-8224 Ph: (802) 660-9585 | Dr Greta Elizabeth Hanson, MD 96 Colchester Ave, Affiliates In Ob/gyn, Burlington, VT 05401-1417 Ph: (802) 655-0505 |
News Archive
Rutin, a bioflavonoid found in certain vegetables and fruits, protects mice against snake venom by minimizing bleeding and inflammation, according to a study performed at the Butantan Institute, a research institution belonging to the government of São Paulo State in Brazil.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.
The Particle Science and Technology Laboratory at Southwest Research Institute has expanded its services to include mask testing in response to the COVID-19 pandemic.
› Verified 7 days ago
Dr. Ira Mark Bernstein, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Department Of Obstetrics And Gynceology, Burlington, VT 05401 Phone: 802-847-5066 Fax: 802-847-2772 | |
Dr. Eleanor Lacava Capeless, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Fahc, Acc 4th Floor, Burlington, VT 05401 Phone: 802-847-5066 | |
Dr. Renju S Raj, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-3450 | |
Charles Warner Ashley, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-5110 | |
Dr. Alexandra Charlotte Fenton, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 96 Colchester Ave, Burlington, VT 05401 Phone: 802-658-0505 | |
Justin A. Deangelis, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-1400 Fax: 802-847-8433 | |
Dr. Adam Buckley, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-8181 |